论文部分内容阅读
约有半数晚期何杰金氏病病人对 MOPP(氮芥、长春新硷、甲苄肼、强的松)方案无效或易复发。作者采用 ABDIC(阿霉素、博莱霉素、氮烯唑胺、罗氮芥、强的松)方案治疗32例对 MOPP 耐药的何杰金氏病病人,其中3例因早期死亡未作评价。29例的组织病理学诊断为结节硬化型23例,混合细胞型5例,未定型1例。所有病例在用 ABDIC 前均曾接受 MOPP 治疗,均系耐药病例。18例曾经放射治疗。淋巴结复发4例,其余25例有淋巴结外波及,其中16例伴淋巴结受累。复发的主要部位是淋巴结、肺和肝。复发时仅3例有 B 组症状。ABDIC 开始前,中数病程期为20个月,平均37(1～130)个月。
About half of Hodgkin’s disease patients are ineffective or prone to recurrence of MOPP (mechlorethamine, vincristine, procarbazine, prednisone) regimen. The authors treated 32 patients with Hodgkin’s disease that were resistant to MOPP using ABDIC (doxorubicin, bleomycin, dacarbazine, carotenoid, prednisone) regimen, of which 3 died of early mortality Evaluation. Histopathology of 29 cases was diagnosed as nodular sclerosis in 23 cases, mixed cell in 5 cases and unconfined in 1 case. All cases were treated with MOPP before ABDIC, are resistant cases. Eighteen patients had radiotherapy. Recurrence of lymph nodes in 4 cases, the remaining 25 cases of lymph node metastasis, of which 16 cases with lymph node involvement. The main site of recurrence is lymph nodes, lungs and liver. Only 3 cases had symptoms of group B when relapse. Before ABDIC began, the median duration of disease was 20 months, an average of 37 (1 ~ 130) months.